Table 1. Background characteristics of the 9 subject groups.
| Units | HIV negative | PHI | NA, CD4 >350 | NA, CD4 200–349 | NA, CD4 50–199 | NA, CD4 <50 | HAD | RX suppressed | Elites | |
|---|---|---|---|---|---|---|---|---|---|---|
| VARIABLE | N | |||||||||
| Subjects | Total per group | 20 | 24 | 20 | 20 | 20 | 20 | 12 | 19 | 8 |
| Site | Ratio SF:GOT | 20:0 | 19:5 | 12:8 | 12:8 | 12:8 | 11:9 | 6:6 | 11:8 | 8:0 |
| Gender | Ratio M:F | 20:0 | 24:0 | 16:4 | 15:5 | 17:3 | 18:2 | 12:0 | 16:3 | 5:3 |
| median (25–75%) | ||||||||||
| Age (years) | years | 36 (29–48) | 34 (28–43) | 42 (36–44) | 45 (35–53) | 43 (38–54) | 42 (38–49) | 42 (38–47) | 43 (38–49) | 49 (42–55) |
| Time since HIV diagnosis | " | 0.14 (0.10–0.19) | 2 (0.7–12) | 4 (0.7–14) | 1 (0.7–12) | 1 (0.1–13) | 2 (4–8) | 2 (0.0–8) | 19 (14–23) | |
| Background Biomarkers | ||||||||||
| Visit CD4 | cells/μL | 762 (688–988) | 559 (401–749) | 491 (409–572) | 240 (222–306) | 122 (96–145) | 20 (8–39) | 55 (35–160) | 548 (283–770) | 869 (721–1070) |
| Visit CD8 | " | 534 (351–683) | 1200 (708–1623) | 909 (694–1142) | 827 (694–1086) | 760 (497–930) | 495 (285–684) | 650 (307–976) | 757 (620–1094) | 702 (401–828) |
| Nadir CD4 | " | 320 (235–370) | 220 (60–285) | 110 (70–177) | 15 (4–26) | 20 (14–105) | 60 (12–220) | |||
| CSF WBC | " | 1 (1–3) | 6 (3–13) | 7 (3–9) | 6 (3–14) | 4 (1–9) | 0 (0–1) | 6 (1–18) | 1 (0–2) | 2 (2–2.8) |
| HIV plasma RNA | log10 copies/mL | 4.6 (4.2–5.5) | 4.1 (3.4–4.6) | 4.8 (4.2–5.3) | 4.8 (4.5–5.1) | 5.4 (4.5–5.9) | 5.3 (4.8–5.7) | 1.6 (1.6–1.6)* | 1.6 (1.6–1.6)* | |
| HIV CSF RNA | " | 2.7 (1.8–3.4) | 3.2 (2.5–3.6) | 4.1 (3.4–4.6) | 3.8 (3.5–4.4) | 3.1 (2.3–3.8) | 3.6 (2.7-.0) | 1.6 (1.6–1.6)* | 1.6 (1.6–1.6)* | |
| Plasma:CSF difference | " | 2.1 (1.7–2.3) | 1.0 (0.1–1.6) | 0.6 (0.4–1.4) | 1.0 (0.6–1.5) | 2.1 (1.6–3.0) | 0.8 (0.4–2.1) | 0 (0–0) | 0 (0–0) | |
| CSF: blood Albumin | ratio | 4.3 (3.4–6.2) | 5.4 (4.5–7.4) | 5.3 (3.9–6.4) | 5.1 (4.1–7.4) | 5.4 (3.6–7.5) | 4.4 (3.7–5.4) | 9.8 (5.8–12.8) | 5.1 (4.5–6.4) | 4.4 (3.9–6.0) |
| Neural Injury Biomarkers | ||||||||||
| CSF NFL | ng/L | 364 (276–479) | 509 (404–975) | 487 (379–584) | 567 (430–685) | 611 (498–1243) | 1861 (715–4600) | 14915 (2576–39738) | 620 (430–710) | 574 (534–751) |
| CSF t-tau | " | 201 (147–238) | 215 (172–294) | 203 (150–273) | 190 (127–280) | 233 (138–308) | 250 (157–368) | 603 (323–1275) | 187 (130–240) | 195 (172–294) |
| QNPZ-4 | Z score | -0.10 (-0.55–0.16) | -0.16 (-0.74–0.04) | -0.07 (-0.63–0.40) | -0.16 (-0.67–0.59) | -0.45 (-1.80–0.11) | -1.42 (-12.58- -0.10) | -2.42 (-5.22- —1.32) | 0.78 (0.04–1.11) | -1.08 (-1.52- -0.28) |
*These log10 values are equivalent to the assigned ’floor’ value of 39 copies/Ml for all values below 40 copies/mL.